What was changed
Catalent was under investor pressure after operational problems and weak stock performance. The company formed a Strategic and Operational Review Committee in 2023 to review its business, strategy, operations and capital allocation.
The turning decision was to run a value-maximizing process rather than simply promise margin repair. In February 2024, Catalent agreed to be acquired by Novo Holdings, with Elliott signing a voting support agreement.
The deal valued Catalent at $16.5B enterprise value. The $63.50 cash price was a 47.5% premium to the 60-day volume-weighted average price before announcement, giving shareholders a clean exit from an uncertain manufacturing turnaround.
What it achieved
Novo Holdings agreed to pay $16.5B enterprise value, $63.50 per share in cash.
Why it worked
The review committee created a board-level mechanism for considering sale alternatives.
Elliott's support agreement lowered execution risk after the deal was signed.
The transaction matched Catalent's biologics assets with a long-term life-sciences owner.
What can be applied
A formal strategic review can turn activist pressure into price discovery instead of a defensive stalemate.
Aftermath
After closing, Catalent was set to leave the NYSE and become private under Novo Holdings. Novo Holdings also planned to sell three fill-finish sites to Novo Nordisk, making the industrial logic explicit.
FOLLOW THE EVIDENCE
The sources
- Catalent, Inc. Form 8-K sec.gov
- Novo Holdings to Acquire Catalent catalent.com